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Dual renin–angiotensin aldosterone (RAAS) blockade is
associated with higher risk of hyperkalemia and has not been
shown, in any outcome trial of validated renal end points,
that is, doubling of creatinine, time to dialysis, or death,
to be superior over other approaches. It shows promise in
advanced proteinuric nephropathy for additional proteinuria
reduction. Whether this additional proteinuria reduction
translates into meaningful outcomes of chronic kidney
disease (CKD) is unknown, as proteinuria change is not a
validated surrogate end point. Until we know the answer to
this question, only those with very high levels of proteinuria
should receive combination RAAS blocking therapy, and they
need to be carefully monitored. Such individuals should be
evaluated for risk of hyperkalemia and should consider use
of a non-dihydropyridine calcium antagonist added to the
single RAAS agent as an alternative for proteinuria reduction.
This provides a safe and effective option for those patients
with advanced nephropathic disease who need additional
proteinuria reduction. In all cases other than advanced
proteinuric nephropathy, there is no evidence of any positive
CKD outcome with dual RAAS blockade. Thus, dual RAAS
blockade cannot be recommended for all CKD patients.
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In the field of cardiology death or sustained dysfunction of
its organ, the heart, count toward significant end points by
regulatory agencies, death or sustained dysfunction of the
nephrologist organ, the kidney, and also counts toward such
events, was defined by the need for dialysis or sustained
doubling of the serum creatinine. These events were obtained
more easily 40–50 years ago when therapies for, the currently
established risk factors of, hypertension, hyperglycemia, and
hyperlipidemia were less well controlled.
Sophistication in clinical trial methodology, that is,
applying power calculation for dialysis outcomes, came later
to nephrologists, as the end points used as outcomes until the
1980s involved changes in iothalamate clearance and urinary
protein excretion and not dialysis, as the cardiovascular event
rates were very high in this cohort. In the 1980s, the concept
of doubling of serum creatinine put forth in the Captopril
trial led to a revolution in the suggestions of the Cardio-renal
panel of the Food and Drug Administration (FDA) with
regard to chronic kidney disease (CKD) outcomes. From
1993 onward, doubling of serum creatinine, dialysis, and
death were considered to be relevant composite end points
for a CKD outcome.
Unfortunately, the incidence of this composite end point
is much lower today than 20 years ago, in part, due to much
better management of known risk factors for progression,
that is, blood pressure and glycemic control.1,2 Subsequently,
‘surrogate’ measures of outcome have become the rule of the
day as they are fast and can deliver a quick message about
implied outcome. Is the quick message delivered misleading?
The FDA argues that in the absence of a ‘hard end point’
such as the start of chronic dialysis, a ‘validated surrogate’
may be used to help assess the outcome. Two simultaneous
conditions are needed to establish a validated surrogate:
(1) the biological marker must be correlated with the clinical
end point; and (2) the marker must fully capture the net
effect of the intervention on the clinical-efficacy end point.3
Thus, a validated surrogate should be linked to the
pathophysiology of disease progression independent of other
variables. An example of a validated surrogate marker would
be blood pressure reduction and accompanying reduction in
cardiovascular events. Given this association between blood
pressure reduction and the concomitant reduction in
cardiovascular risk, one has to ask whether a change in a
purported surrogate, that is, microalbuminuria, results in an
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altered natural history of disease progression to nephropathy
independent of other variables, that is, blood pressure
reduction. In the recent opinion of the FDA, the answer
was ‘No’.4
This preamble is relevant to the question posed: is dual
renin–angiotensin aldosterone (RAAS) blockade desirable to
slow nephropathy progression? As always, the answer lies in
the definition of nephropathy progression. Is it doubling of
creatinine, time to dialysis or death? The answer is ‘No’. Then,
is it change in a non-validated surrogate, that is, albuminuria?
The answer is ‘Yes’ (Figure 1).
There is clear evidence that pharmacological blockade of
the RAAS with angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin receptor blockers (ARBs) together
further reduces both albuminuria and proteinuria.5,6 The
question, however, is whether this is consistent with long-
term renoprotection. Many papers have been written about
dual blockade of the RAAS resulting in an additional 20%
reduction in albuminuria and equating this to renoprotec-
tion.5–7 Therefore, the first question is, is this conclusion
valid? If it is valid, does it hold across the range of
albuminuria, that is, 430mg/day up to 10,000mg/day, or
is it relevant only in the macroalbuminuria range, that is,
X300mg/day?
To explore this question, there have been several studies
investigating the validity of microalbuminuria as a correlate
of kidney disease, and also the changes in both micro-
albuminuria and albuminuria in reference to blood pressure
and other variables that can affect its genesis. Microalbumi-
nuria clearly does not meet the criteria for a validated
surrogate because of its variability and lack of predictability,8
as well as its lack of correlation with early pathological
changes in the nephropathy, that is, mesangial expansion in
diabetes.9 Thus, it is not a validated surrogate for CKD
outcomes, and hence all prior studies quoted by my
opponent, Dr Weir, for dual RAAS blockade on this marker
are invalid.
Evidence also points to the fact that changes in CKD
outcome as reflected by albuminuria reduction by RAAS
blockade are much more predictive of CKD outcomes late
rather than early in the course of nephropathy.10 Thus, as is
evident in the ABCD (Appropriate Blood Pressure Control
and Diabetes) Trial, aggressive early control of blood
pressure, regardless of antihypertensive class, among those
with microalbuminuria, hypertension, and type 2 diabetes,
results in a marked slowing of CKD progression as assessed
by change in the creatinine clearance slope. As noted earlier
to obtain an outcome recognized by regulatory authorities,
one would require over a decade of follow-up to garner
meaningful endpoint data.11 In such patients, it is very
difficult to imagine that dual RAAS blockade would offer any
advantage on CKD outcomes.
Changes in macroalbuminuria or proteinuria, that is,
X300mg/day of albumin with RAAS blockade, are more
positive in the context of CKD outcomes, that is, doubling of
creatinine and need for dialysis, but they are all retrospective
data from randomized clinical trials and none involving dual
RAAS blockade.12
A meta-analysis by Kunz et al. clearly shows an additional
20% reduction in albuminuria when dual RAAS blockade is
used, but this is in the context of an additional 3–5mmHg
reduction in systolic blood pressure.6 This has been observed
by others as well.13 Given that all retrospective trial analyses
demonstrate that a 430% reduction in proteinuria from
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Figure 1 |Relationship between glycemia and renal injury.
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baseline correlates with a slower decline in glomerular
filtration rate among those with advanced proteinuric
nephropathy, use of dual RAAS blockade to provide an
additional 20% reduction may be meaningful. However, we
have no outcome data to support this assertion yet.
The COOPERATE trial would have provided some insight,
but was found to have many discrepancies in data and was
thus unreliable.6,14 All other clinical studies that evaluated
dual RAAS blockade have done so in patients with lesser
degrees of albuminuria and are hence not valid. The AVOID
trial is an exception, in which advanced diabetic patients with
proteinuric kidney disease were randomized to either a
placebo or a direct renin inhibitor on background therapy
with an ARB.15 However, the data from this trial were
consistent with the findings of Kunz et al., and hence do not
provide meaningful endpoint data.
Three ongoing trials will answer the question regarding
dual RAAS blockade and CKD progression definitely. The VA
NEPHRON-D is an ongoing double-blind randomized,
controlled trial within the Veteran’s Administration powered
for CKD progression as the FDA definition and properly
powered to address the issue.16 The second is the ALTITUDE
(Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal
Endpoints), a large randomized double-blind, placebo-
controlled outcome trial in diabetic nephropathy patients
that will also contribute to the answer regarding the effect of
dual RAAS blockade using a direct renin inhibitor with an
ACEI or ARB on cardiovascular and CKD outcomes.17 The
third trial that will assess the effect of dual RAAS blockade on
kidney disease progression is the HALT-PKD study.18 This is
a trial of over 1000 patients with polycystic kidney disease
assessing the effects of dual RAAS blockade on kidney size
over time. Until the results of these trials are completed, we
really cannot make any claims about dual RAAS blockade and
progression of nephropathy. Note that neither of these trials
is due for completion until 2012–2013.
The other major problem with dual RAAS blockade is that
of differentiating its effects on CKD outcome independently
from blood pressure reduction. Carefully controlled animal
studies show that better blood pressure control results in
better renal outcomes even with RAAS blockade.19 In
addition, dual RAAS blockade offers better blood pressure
control.20 Thus, it will be difficult to assess renoprotection
even in the ongoing well-designed trials of dual RAAS
blockade independent of this risk factor.
In all but one clinical study to date, AVOID, using dual
RAAS blockade resulted in an added 3–5mmHg reduction in
systolic blood pressure, an amount that is statistically
significant and epidemiologically relevant to CKD outcomes.
How can one then say that dual RAAS blockade provides
better CKD protection without a control group at compar-
able blood pressure levels? The answer to this question is
unclear to me.13,20
Finally, safety concerns regarding dual RAAS blockade
must be mentioned. This is especially true in the context of
advanced CKD. If one accepts the notion that dual RAAS
blockade offers no additional benefit on further slowing of
early nephropathy, with normo- or microalbuminuria
progression, then only those with advanced proteinuric
nephropathy should garner benefit. These are predominantly
the groups that are being studied in VA NEPHRON D and
ALTITUDE trials.
Previous studies have shown a risk for hyperkalemia in
individuals with advanced proteinuric nephropathy requiring
dual RAAS for proteinuria or blood pressure reduction.7,21–23
In a recent study, however, the risks for hyperkalemia
associated with dual RAAS blockade were highest among
those already on a maximal ACEI or ARB and an appropriately
dosed diuretic that had a second RAAS agent added.
Specifically, those with an estimated glomerular filtration
rate o45ml/min and a baseline potassium 44.5mEq/l were
at highest risk.22
In short, dual RAAS blockade shows promise in advanced
proteinuric nephropathy for additional proteinuria reduction;
however, its effect on CKD outcome is unknown, as proteinuria
is not a validated surrogate end point. Until we know the
answer to this question, only those with very high levels of
proteinuria should receive combination RAAS blocking
therapy. Moreover, those people should be evaluated for risk
of hyperkalemia and should consider use of a non-dihydropyr-
idine calcium antagonist combined with the single RAAS agent
for proteinuria reduction.24 Non-dihydropyridine calcium
antagonists reduce proteinuria and provide additive reductions
when combined with renin–angiotensin system blockers.24 This
provides a safe and effective option for those patients with
advanced nephropathic disease. In all cases other than
advanced proteinuric nephropathy, there is no evidence of
any positive CKD outcome. Thus, dual RAAS blockade cannot
be recommended for all CKD patients.
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